Document Detail


Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells.
MedLine Citation:
PMID:  10655438     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Certain antimitotic drugs have antitumor activities that apparently result from interactions with nontubulin components involved in cell growth and/or apoptotic cell death. Indanocine is a synthetic indanone that has been identified by the National Cancer Institute's Developmental Therapeutics Program as having antiproliferative activity. In this study, we characterized the activity of this new antimitotic drug toward malignant cells. METHODS: We tested antiproliferative activity with an MTT [i.e., 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay, mitochondrial damage and cell cycle perturbations with flow cytometry, caspase-3 activation with fluorometry, alterations of the cytoskeletal components with immunofluorescence, and antimicrotubule activity with a tubulin polymerization assay. RESULTS/CONCLUSIONS: Indanocine is a cytostatic and cytotoxic indanone that blocks tubulin polymerization but, unlike other antimitotic agents, induces apoptotic cell death in stationary-phase multidrug-resistant cancer cells at concentrations that do not impair the viability of normal nonproliferating cells. Of the seven multidrug-resistant cell lines tested, three (i.e., MCF-7/ADR, MES-SA/DX5, and HL-60/ADR) were more sensitive to growth inhibition by indanocine than were their corresponding parental cells. Confluent multidrug-resistant cells (MCF-7/ADR), but not drug-sensitive cancer cells (MCF-7) or normal peripheral blood lymphocytes, underwent apoptotic cell death 8-24 hours after exposure to indanocine, as measured by sequential changes in mitochondrial membrane potential, caspase activity, and DNA fragmentation. Indanocine interacts with tubulin at the colchicine-binding site, potently inhibits tubulin polymerization in vitro, and disrupts the mitotic apparatus in dividing cells. IMPLICATIONS: The sensitivity of stationary multidrug-resistant cancer cells to indanocine suggests that indanocine and related indanones be considered as lead compounds for the development of chemotherapeutic strategies for drug-resistant malignancies.
Authors:
L M Leoni; E Hamel; D Genini; H Shih; C J Carrera; H B Cottam; D A Carson
Related Documents :
1356238 - Adaptation of mouse leukemia cells l1210 to vincristine. evidence for expression of p-g...
7913708 - Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is ...
7931778 - An assay to measure adriamycin binding in osteosarcoma cells.
14127588 - Radiosensitivity of several dehydrogenases and transaminases during sporogenesis of bac...
7903328 - Evidence for paracrine somatostatinergic regulation of gastrin gene expression by doubl...
9422318 - Fibroepithelial polyps of the anus: a histologic, immunohistochemical, and ultrastructu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the National Cancer Institute     Volume:  92     ISSN:  0027-8874     ISO Abbreviation:  J. Natl. Cancer Inst.     Publication Date:  2000 Feb 
Date Detail:
Created Date:  2000-02-28     Completed Date:  2000-02-28     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7503089     Medline TA:  J Natl Cancer Inst     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  217-24     Citation Subset:  IM    
Affiliation:
Department of Medicine and The Sam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla 92093, USA. lleoni@ucsd.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects
Caspase 3
Caspases / drug effects
Coloring Agents / diagnostic use
DNA Fragmentation
Drug Resistance, Multiple*
Drug Resistance, Neoplasm*
Enzyme Activation / drug effects
Enzyme Precursors / drug effects
Flow Cytometry
Fluorescent Antibody Technique
Fluorometry
Humans
Indans / pharmacology*
Microtubules / drug effects*,  metabolism
Neoplasms / drug therapy*,  metabolism,  pathology
Polymers
Protein Binding / drug effects
Tetrazolium Salts / diagnostic use
Thiazoles / diagnostic use
Tubulin / drug effects*,  metabolism
Tumor Cells, Cultured
Grant Support
ID/Acronym/Agency:
CA78040-01/CA/NCI NIH HHS; GM23200/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Coloring Agents; 0/Enzyme Precursors; 0/Indans; 0/Polymers; 0/Tetrazolium Salts; 0/Thiazoles; 0/Tubulin; 0/indanocine; 298-93-1/thiazolyl blue; EC 3.4.22.-/CASP3 protein, human; EC 3.4.22.-/Caspase 3; EC 3.4.22.-/Caspases
Comments/Corrections
Comment In:
J Natl Cancer Inst. 2000 Feb 2;92(3):182-3   [PMID:  10655426 ]
J Natl Cancer Inst. 2000 Sep 20;92(18):1535-6   [PMID:  10995814 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Rese...
Next Document:  Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast ca...